<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550771</url>
  </required_header>
  <id_info>
    <org_study_id>P05048</org_study_id>
    <nct_id>NCT00550771</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)</brief_title>
  <official_title>Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence of cardiac dysfunction in subjects with
      human epidermal growth factor receptor 2 (HER2) positive breast cancer treated with either
      doxorubicin or pegylated liposomal doxorubicin (PLD), both in combination with trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2007</start_date>
  <completion_date type="Actual">August 23, 2010</completion_date>
  <primary_completion_date type="Actual">August 23, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year</measure>
    <time_frame>8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment</time_frame>
    <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy</measure>
    <time_frame>During the 8 courses of chemotherapy</time_frame>
    <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy</measure>
    <time_frame>During 1 year of trastuzumab therapy</time_frame>
    <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived Without Relapse</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Relapse-free survival would have been determined by Kaplan-Meier method.
This was not calculated, since the 2 year follow-up was curtailed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Doxorubicin Based Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, cyclophosphamide, paclitaxel, trastuzumab</intervention_name>
    <description>doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
    <arm_group_label>Doxorubicin Based Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLD, cyclophosphamide, trastuzumab, paclitaxel</intervention_name>
    <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
    <arm_group_label>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</arm_group_label>
    <other_name>pegylated liposomal doxorubicin (SCH 200746)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with operable, node-positive or high-risk node-negative (see #3 below)
             HER2-positive breast carcinoma are eligible for the study, provided they satisfy the
             following criteria.

               -  Subjects must demonstrate willingness to and be able to participate in the study
                  and to adhere to dose and visit schedules

               -  Subjects must be of female gender and &gt;= 18 years of age

               -  Subjects must have been diagnosed with operable, histologically confirmed
                  adenocarcinoma of the breast with no clinical or radiological evidence of
                  metastatic disease but with otherwise high or intermediate risk tumor
                  characteristics:

                    -  node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node
                       involvement], &amp; M [matastases]) OR

                    -  node-negative AND at least one of the following features:

                         -  Tumor &gt;2 cm or

                         -  Tumor &gt;1 cm and

                              -  Negative estrogen receptor/progesterone receptor (ER/PR) or

                              -  Malignancy Grade 2-3 or

                              -  Presence of peritumoral vascular invasion or

                              -  Age &lt;35 years

               -  HER2-positive by fluorescence in situ hybridization (FISH)(with gene
                  amplification) or 3+ using

        immunohistochemistry

          -  Subjects must have had complete resection (R0) of the primary tumor and axillary lymph
             nodes (or must have negative sentinel node[s])

          -  Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition
             (MUGA) scan or echocardiogram (ECHO) &gt;=55%

          -  Easter Cooperative Oncology Group (ECOG)-performance status of 0-1

          -  Adequate postoperative bone marrow function with neutrophils &gt;=1.5 x 10^9/l, platelets
             &gt;=100 x 10^9/l and hemoglobin &gt;= lower limit of normal (LLN)

          -  Adequate renal function: calculated creatinine clearance &gt;=50 ml/min

          -  Adequate postoperative liver function with a total bilirubin &lt; upper limit of normal
             (ULN), alkaline phosphatase &lt;2.5 times the ULN and aspartate aminotransferase (AST)
             &lt;1.5 times the ULN

          -  Subjects must be free of any clinically relevant disease that would, in the principal
             investigator's and/or sponsor's opinion, interfere with the conduct of the study or
             study evaluations

          -  Subjects of childbearing potential (including women who are less than one year
             postmenopausal and will be sexually active during the study) must agree to use a
             medically accepted method of contraception, while receiving protocol-specified
             medication and for 30 days (or as per local requirements) after stopping the
             medication or be surgically sterilized prior to screening

          -  Subjects must be able to provide written informed consent

        Exclusion Criteria:

          -  Subject who meets any of the following exclusion criteria will be disqualified from
             participation in the study:

               -  Clinical or radiological evidence of metastatic disease

               -  Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast
                  cancer prior to randomization

               -  Clinically significant pericardial effusion

               -  Serious cardiac illness including, but not confined to

                    -  history of documented congestive heart failure

                    -  history of any form of cardiomyopathy or active treatment for any form of
                       cardiomyopathy

                    -  history of angina pectoris or documented transmural myocardial infarction,
                       or active angina pectoris requiring medication

                    -  serious ventricular arrhythmias requiring medication or implantable
                       cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular
                       arrhythmias

                    -  clinically significant valvular disease

                    -  poorly controlled arterial hypertension (systolic blood pressure (BP) &gt;180
                       mmHg, diastolic BP &gt;100 mmHg)

               -  Sensory/motor neuropathy &gt; grade 2 as defined by National Cancer Institure -
                  Common Toxicity Criteria (NCI-CTC)

               -  Pregnancy, or intending to become pregnant during the study

               -  Nursing (breastfeeding) or intending to be nursing during the study

               -  Any of the following clinical conditions:

                    -  Chronic obstructive pulmonary disease, requiring chronic treatment

                    -  Clinically significant active infections

                    -  A history of a psychological illness of condition, preventing the subject to
                       understand the requirements of the study

                    -  Unstable regulation of diabetes mellitus

               -  A situation or condition that, in the opinion of the investigator, may interfere
                  with optimal participation in the study

               -  Is on staff, affiliated with, or a family member of the staff personnel directly
                  involved with this study

               -  Usage of any investigational product within 30 days prior to enrollment

               -  Participation in any other interventional clinical study involving drug, device
                  or biological. This would not prohibit the patient from participating in a
                  quality of life (QOL), questionnaire, blood collection, or observational study.

               -  Allergy to or sensitivity to the study drug or its excipients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <results_first_submitted>August 26, 2011</results_first_submitted>
  <results_first_submitted_qc>August 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2011</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
          <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
        </group>
        <group group_id="P2">
          <title>Doxorubicin Based Regimen</title>
          <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued for study-related reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
          <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
        </group>
        <group group_id="B2">
          <title>Doxorubicin Based Regimen</title>
          <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age information was for the intent-to-treat (ITT) population (n=59 for doxorubicin arm, n=120 for PLD arm). ITT was defined as all participants who were randomized and received at least 1 dose of any study medication.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="10.97"/>
                    <measurement group_id="B2" value="52.5" spread="9.32"/>
                    <measurement group_id="B3" value="50.9" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>ITT population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year</title>
        <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
        <time_frame>8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment</time_frame>
        <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.
Each participant could not contribute more than 1 event.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
            <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
          </group>
          <group group_id="O2">
            <title>Doxorubicin Based Regimen</title>
            <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year</title>
          <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
          <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.
Each participant could not contribute more than 1 event.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy</title>
        <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
        <time_frame>During the 8 courses of chemotherapy</time_frame>
        <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
            <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
          </group>
          <group group_id="O2">
            <title>Doxorubicin Based Regimen</title>
            <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy</title>
          <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
          <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Level 1 Cardiotoxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 2 Cardiotoxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inability to Administer Trastuzumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy</title>
        <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
        <time_frame>During 1 year of trastuzumab therapy</time_frame>
        <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
            <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
          </group>
          <group group_id="O2">
            <title>Doxorubicin Based Regimen</title>
            <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy</title>
          <description>Cardiac events defined as:
Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of &gt;10 percentage points from baseline and to ≤50% LVEF
Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of &gt;10 percentage points from baseline and to &lt;50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks.</description>
          <population>ITT, defined as all participants who were randomized and received at least 1 dose of any study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Level 1 Cardiotoxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 2 Cardiotoxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inability to Administer Trastuzumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Survived Without Relapse</title>
        <description>Relapse-free survival would have been determined by Kaplan-Meier method.
This was not calculated, since the 2 year follow-up was curtailed.</description>
        <time_frame>Approximately 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin (PLD) Based Regimen</title>
            <description>PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)</description>
          </group>
          <group group_id="O2">
            <title>Doxorubicin Based Regimen</title>
            <description>doxorubicin 60 mg/m^2 intravenous (IV) push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived Without Relapse</title>
          <description>Relapse-free survival would have been determined by Kaplan-Meier method.
This was not calculated, since the 2 year follow-up was curtailed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLD Based Regimen</title>
        </group>
        <group group_id="E2">
          <title>Doxorubicin Based Regimen</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PLEUROPERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="16" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="72" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="45" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E2" events="38" subjects_affected="20" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="65" subjects_affected="34" subjects_at_risk="120"/>
                <counts group_id="E2" events="33" subjects_affected="17" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="100" subjects_affected="63" subjects_at_risk="120"/>
                <counts group_id="E2" events="70" subjects_affected="35" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="41" subjects_affected="28" subjects_at_risk="120"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="37" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="72" subjects_affected="30" subjects_at_risk="120"/>
                <counts group_id="E2" events="27" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="102" subjects_affected="51" subjects_at_risk="120"/>
                <counts group_id="E2" events="71" subjects_affected="36" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="82" subjects_affected="41" subjects_at_risk="120"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E2" events="23" subjects_affected="14" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="120"/>
                <counts group_id="E2" events="26" subjects_affected="14" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="30" subjects_affected="18" subjects_at_risk="120"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NEUROTOXICITY</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="35" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="120"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="75" subjects_affected="59" subjects_at_risk="120"/>
                <counts group_id="E2" events="55" subjects_affected="45" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" events="183" subjects_affected="79" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="68" subjects_affected="35" subjects_at_risk="120"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>SKIN HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigators (PIs) agree not to publish/publicly present any interim study results without prior sponsor written consent. The PIs further agree to provide 45 days written notice to the sponsor, prior to submission for publication or presentation, to permit the sponsor to review abstracts/manuscripts, which report any study results. The sponsor has the right to review/comment. If the parties disagree, the PIs agree to meet with the sponsor, prior to submission, to discuss/resolve.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Any follow-up data from this study should be considered with caution as the planned 2-year follow-up was curtailed because of administrative reasons.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

